Tissue-source effect on mesenchymal stem cells as living biodrugs for heart failure: Systematic review and meta-analysis

doi:10.4330/wjc.v16.i8.469

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (229)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-5) series.

Item

Count

PDF

HTML

184

Figures (1-5)

Tables (1-5)

Sum=205

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=9

Publishing Process of This Article

Item

Count

Browse

Download

Sum=3

Aug 26, 2024 (publication date) through Aug 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Cardiol. Aug 26, 2024; 16(8): 469-483
Published online Aug 26, 2024. doi: 10.4330/wjc.v16.i8.469

Open in New Tab Full Size Figure Download Figure

Figure 1 Study selection flow diagram of preferred reporting item for systematic reviews and meta-analysis. RCTs: Randomized controlled trials.

Open in New Tab Full Size Figure Download Figure

Figure 2 Risk of bias assessment graph. UC-MSCs: Umbilical-cord-derived mesenchymal stem cells; BM-MSCs: Bone-marrow-derived mesenchymal stem cell.

Open in New Tab Full Size Figure Download Figure

Figure 3 Forest plot of left ventricular ejection fraction change from baseline to 6 mo of follow-up. A: Umbilical-cord-derived mesenchymal stem cells; B: Bone-marrow-derived mesenchymal stem cells. UC-MSCs: Umbilical cord-derived mesenchymal stem cells; BM-MSCs: Bone marrow-derived mesenchymal stem cell; MI: Myocardial infarction; HF: Heart failure.

Open in New Tab Full Size Figure Download Figure

Figure 4 Forest plot of left ventricular ejection fraction change from baseline to 12 mo follow-up. A: Umbilical cord-derived mesenchymal stem cells; B: Bone marrow-derived MSCs. UC-MSCs: Umbilical-cord-derived mesenchymal stem cells; BM-MSCs: Bone-marrow-derived mesenchymal stem cell; MI: Myocardial infarction; HF: Heart failure.

Open in New Tab Full Size Figure Download Figure

Figure 5 Forest Plot of major adverse events. A and B: Mortality in umbilical-cord-derived mesenchymal stem cells (A) and bone-marrow-derived mesenchymal stem cells (B); C and D: Major cardiac adverse events in UC-MSCs (C) and BM-MSCs (D); E and F: Rehospitalization in UC-MSCs (E) and BM-MSCs (F). UC-MSCs: Umbilical-cord-derived mesenchymal stem cells; BM-MSCs: Bone-marrow-derived mesenchymal stem cells.

Citation: Safwan M, Bourgleh MS, Aldoush M, Haider KH. Tissue-source effect on mesenchymal stem cells as living biodrugs for heart failure: Systematic review and meta-analysis. World J Cardiol 2024; 16(8): 469-483
URL: https://www.wjgnet.com/1949-8462/full/v16/i8/469.htm
DOI: https://dx.doi.org/10.4330/wjc.v16.i8.469